- Open
- 110.00
- High
- 110.00
- Low
- 108.40
- Close
- 108.80
- Change
- +0.40 (0.37%)
- Volume
- 511,002
⌘K
| 4 Jun 2026 | 07:10:09 | Incanthera plc – Corporate Update & Board Changes |
| 2 Jun 2026 | 07:00:02 | Notice of AGM & Annual Report & Accounts |
| 27 May 2026 | 07:00:03 | Final Results |
| 5 May 2026 | 07:00:18 | IMM initiatesIND-Enabling Program for Kapiglucagon |
| 10 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 23 Mar 2026 | Annual Report for the year ended 31 December 2025 | |
| 15 May 2025 | Annual Report and Accounts (to 2024-12-31) |
ImmuPharma PLC is a London-based company with research facilities in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). Its primary focus is on creating groundbreaking medications to address critical health issues.
| 4 Jun 2026 | 07:10:09 | Incanthera plc – Corporate Update & Board Changes |
| 2 Jun 2026 | 07:00:02 | Notice of AGM & Annual Report & Accounts |
| 27 May 2026 | 07:00:03 | Final Results |
| 5 May 2026 | 07:00:18 | IMM initiatesIND-Enabling Program for Kapiglucagon |
| 10 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 23 Mar 2026 | Annual Report for the year ended 31 December 2025 | |
| 15 May 2025 | Annual Report and Accounts (to 2024-12-31) |
ImmuPharma PLC is a London-based company with research facilities in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). Its primary focus is on creating groundbreaking medications to address critical health issues.
| 10 Apr 2026 | 07:00:04 | Holding(s) in Company |
| 9 Apr 2026 |
| ImmuPharma: P140 partnering discussions continue; overwhelming backing for investment round |
| 27 Mar 2026 | ImmuPharma shares surge 20% as P140 partnering talks advance |
| 27 Mar 2026 | ImmuPharma advances P140 partnering talks as patent progress and new study data strengthen programme |
| 10 Apr 2026 | 07:00:04 | Holding(s) in Company |
| 9 Apr 2026 |
| ImmuPharma: P140 partnering discussions continue; overwhelming backing for investment round |
| 27 Mar 2026 | ImmuPharma shares surge 20% as P140 partnering talks advance |
| 27 Mar 2026 | ImmuPharma advances P140 partnering talks as patent progress and new study data strengthen programme |